Bloomston M,Frankel WL,Petrocca F,Volinia S,Alder H .2007 .MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. The Journal of American Medical Association, : 171901-1908.
Jemal A,Devesa SS,Hartge P,Tucker MA .2001 .Recent trends in cutaneous melanoma incidence among whites in the United States. Journal of the National Cancer Institute, 93(9) : 678-683.
Cancer Society American .2020 .- m a-s k i n-c a n c e r/a b o u t/k e y-s t a t i s t i c s. , : 2021.
Biomedicines .2022 .. , 10(4) : .
Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I .2021 .. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. A Cancer Journal of Clinicians, 71(3) : 209-249.
Balch CM. .1992 .Cutaneous melanoma: prognosis and treatment results worldwide. Seminars in Surgical Oncology, 8(6) : 400-414.
Cascinelli N,Zurrida S,Galimberti V,Bartoli C,Bufalino R .1994 .Acral lentiginous melanoma. A histological type without prognostic significance. The Journal of Dermatologic Surgery and Oncology, 20(12) : 817-822.
Chang AE,Karnell LH,Menck HR .1998 .The American College of Surgeons Commission on Cancer and the American Cancer Society. , 83(8) : 1664-1678.
Ahmed B,Qadir MI,Ghafoor S.,Malignant S.,Treatment. S. .2020 .Critical reviews in eukaryotic gene expression. , 30(4) : 291-297.
Edwards BK,Howe HL,Ries LA,Thun MJ,Rosenberg HM . .Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S.. , : .
.2002 .cancer burden. Cancer, 94(10) : 2766-2792.
Elwood JM,Gallagher RP JM .1983 .Site distribution of malignant melanoma. Canadian Medical Association Journal, 128(12) : 1400-1404.
Read RL,Haydu L,Saw RP,Quinn MJ,Shannon K .2015 .Intransit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Annals of Surgical Oncology, 22(2) : 475-481.
.2022 .Recent Advances in Immunotherapy for the Treatment of Malignant Melanoma. Current Pharmaceutical Design, 28(29) : 2363-2374.
Long GV,Swetter SM,Menzies AM,Gershenwald JE,Scolyer RA .2023 .Cutaneous melanoma. Lancet, 402(10400) : 485-502.
Uhara H. .2019 .Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. International Journal of Clinical Oncology, 24(12) : 1508-1514.
Livingstone A,Agarwal A,Stockler MR,Menzies AM,Howard K .2020 .Preferences for Immunotherapy in Melanoma: A Systematic Review. Annals of Surgical Oncology, 27(2) : 571-584.
JB Haanen .2013 .Immunotherapy of melanoma. European Journal of Cancer Supplements, 11(2) : 97-105.
Zappasodi R,Sirard C,Li Y,Budhu S,Abu-Akeel M .2019 .Rational design of anti-GITR-based combination immunotherapy. Nature Medicine, 25(5) : 759-766.
Liu BL,Robinson M,Han ZQ,Branston RH,English C .2003 .5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4) : 292-303.
MacKie RM,Stewart B,Brown SM .2001 .Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet, 357(9255) : 525-526.
Johnson DB,Puzanov I,Kelley MC .2015 .Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy, 7(6) : 611-619.
Senzer NN,Kaufman HL,Amatruda T,Nemunaitis M,Reid T .2009 .Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. Journal of Clinical Oncology, 27(34) : 5763-5771.
Andtbacka RHI,Collichio F,Harrington KJ,Middleton MR,Downey G .2019 .Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. Journal of Immunotherapy of Cancer, 7(1) : 145.
Mancuso P,Tricarico R,Bhattacharjee V,Cosentino L,Kadariya Y .2019 .Thymine DNA glycosylase as a novel target for melanoma. Oncogene, 38(19) : 3710-3728.
Lugowska I,Teterycz P,Rutkowski P .2018 .Immunotherapy of melanoma. Contemporary Oncology (Pozn), 22(1a) : 61-67.
Hunder NN,Wallen H,Cao J,Hendricks DW,Reilly JZ .2008 .Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 358(25) : 2698-2703.
Innamarato P,Kodumudi K,Asby S,Schachner B,Hall M .2020 .Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Molecular Therapy, 28(10) : 2252-2270.
Villani A,Scalvenzi M,Fabbrocini G,Ocampo-Candiani J,Ocampo-Garza SS .2021 .Looking into a Better Future: Novel Therapies for Metastatic Melanoma. Dermatology and Therapy (Heidelb), 11(3) : 751-767.
Shi H,Lan J,Yang J .2020 .Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, : 124883-117.
Buchbinder EI,Hodi FS .2016 .Melanoma in 2015: Immunecheckpoint blockade - durable cancer control. Nature Reviews Clinical Oncology, 13(2) : 77-78.
Khushalani NI,Diab A,Ascierto PA,Larkin J,Sandhu S .2020 .Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology, 16(28) : 2165-2175.
Spitler LE,Boasberg P,O'Day S,Hamid O,Cruickshank S .2015 .Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. American Journal of Clinical Oncology, 38(1) : 61-67.
Corrie PG,Marshall A,Dunn JA,Middleton MR,Nathan PD .2014 .Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, 15(6) : 620-630.
Weber J,Mandala M,Del Vecchio M,Gogas HJ,Arance AM .2017 .Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 377(19) : 1824-1835.
Zhang K .2018 .-767 promoted cell proliferation in human melanoma by suppressing CYLD expression. , : 641272-278.
Rajkumar S,Berry D,Heney KA,Strong C,Ramsay L .2022 .Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell Reports, 39(1) : 110634.
Postow MA,Callahan MK,Wolchok JD .2015 .Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 33(17) : 1974-1982.
Haugh AM,Johnson DB .2019 .Management of V600E and V600K BRAF-Mutant Melanoma. , 20(11) : 81.
Schadendorf D,Hodi FS,Robert C,Weber JS,Margolin K .2015 .Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 33(17) : 1889-1894.
Chiou VL,Burotto M. .2015 .Pseudoprogression and ImmuneRelated Response in Solid Tumors. Journal of Clinical Oncology, 33(31) : 3541-3543.
Wilhelm SM,Carter C,Tang L,Wilkie D,McNabola A .2004 .9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64(19) : 7099-7109.
Flaherty KT,Lee SJ,Schuchter LM,Flaherty LE,Wright JJ .2010 .Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. Journal of Clinical Oncology, 28(15) : 8511-8511.
Ribas A,Kim KB,Schuchter LM,Gonzalez R,Pavlick AC .2011 .BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, : suppl8509-15.
Chapman PB,Hauschild A,Robert C,Larkin JMG,Haanen JBAG .2012 .Updated overall survival (OS) results for BRIM3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. Journal of Clinical Oncology, 30(15) : 8502-8502.
Kefford R,Arkenau H,Brown MP,Millward M,Infante JR .2010 .Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Journal of Clinical Oncology, 28(15) : 8503-8503.
Ives NJ,Suciu S,Eggermont AMM,Kirkwood J,Lorigan P .2017 .Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. European Journal of Cancer, : 82171-183.
Agarwala SS,Lee SJ,Yip W,Rao UN,Tarhini AA .2017 .Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). Journal of Clinical Oncology, 35(8) : 885-892.
Mohr P,Hauschild A,Trefzer U,Enk A,Tilgen W .2015 .Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. Journal of Clinical Oncology, 33(34) : 4077-4084.
Eigentler TK,Gutzmer R,Hauschild A,Heinzerling L,Schadendorf D .2016 .Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Annals of Oncology, 27(8) : 1625-1632.
Sosman JA,Kim KB,Schuchter L,Gonzalez R,Pavlick AC .2012 .Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine, 366(8) : 707-714.
Trunzer K,Pavlick AC,Schuchter L,Gonzalez R,McArthur GA .2013 .Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(14) : 1767-1774.
Survival Overall .2016 .Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 34(8) : 871-878.
Robert C,Karaszewska B,Schachter J,Rutkowski P,Mackiewicz A .2015 .Improved overall survival in melanoma with combined dabrafenib and trametinib. New England Journal of Medicine, 372(1) : 30-39.
BREAK-MB .2012 .A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). Journal of Clinical Oncology, : 308501-8501.
Wolchok JD,Chiarion-Sileni V,Gonzalez R,Rutkowski P,Grob JJ .2017 .Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377(14) : 1345-1356.
Fusi A,Dalgleish A .2017 .The importance for immunoregulation for long-term cancer control. Future Oncology, 13(18) : 1619-1632.
Zhengyun Zou .2018 ."Research Progress on Targeted and Immunotherapy for Advanced Malignant Melanoma.". Modern Oncology, 26(12) : 1970-1974.
.2015 .BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. Radiotherapy and oncology : Journal of the European Society for Therapeutic Radiology and Oncology, : 117.
Cohen-Inbar O. PS1 .2016 .- 140 The Effect of Timing of Stereotactic Radiosurgery Treatment of Melanoma Brain Metastases Treated with Ipilimumab. Canadian Journal of Neurological Sciences, 43(S4) : S6-S7.
Markovic SN,Erickson LA,Rao RD,Weenig RH,Pockaj BA .2007 .Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clinic Proceedings, 82(3) : 364-380.
Kaskel P,Sander S,Kron M,Kind P,Peter RU .2001 .Outdoor activities in childhood: a protective factor for cutaneous melanoma? Results of a case-control study in 271 matched pairs. British Journal of Dermatology, 145(4) : 602-609.
.1993 .Study of sunbathing habits in children and adolescents: application to the prevention of melanoma. , 186(2) : 94-98.
Montague M,Borland R,Sinclair C .2001 .Skin cancer control and 20 years of population-based campaigning. Health Education and Behavior, 28(3) : 290-305.
.2006 .Clinical outcomes from skin screening clinics within a community-based melanoma screening program. Journal of American Academy of Dermatology, 54(1) : 105-114.
Marks R. .1995 .An overview of skin cancers. Incidence and causation. Cancer, 75(2 Suppl)) : 607-612.
MI Qadir .2016 .Skin cancer: Etiology and management. Pakistan Journal of Pharmaceutical Sciences, 29(3) : 999-1003.
. .To read the copy of this license please visit: https://creativecommons. , : .